• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>One E-Commerce Corporation

One E-Commerce Corporation

Spark Therapeutics Inc ONCE

Last Price$73.64Day Change (%)7.03%
Open Price$68.49Day Change ($)4.84
Day Range68.37–73.6652-Week Range40.16–79.50

As of Fri 5/29/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. UPDATE: Attention FIFA: Here's how to take a bribe without getting caught

    UPDATE: Attention FIFA: Here's how to take a bribe without getting caught

  2. Kolltan Pharmaceuticals Announces Presentation of KTN3379 Interim Phase 1b Data at 2015 American Society of Clinical Oncology Annual Meeting

    Kolltan Pharmaceuticals Announces Presentation of KTN3379 Interim Phase 1b Data at 2015 American Society of Clinical Oncology Annual Meeting

  3. ImmunoGen’s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity for Patients with Platinum-Resistant Ovarian Cancer

    ImmunoGen’s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity for Patients with Platinum-Resistant Ovarian Cancer

  4. Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting

    Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting

  5. Following National Vote, 24 of America's Most Courageous Canines Chosen to Compete for Title as America's Top Dog

    Following National Vote, 24 of America's Most Courageous Canines Chosen to Compete for Title as America's Top Dog

  6. Updated Data Showed Genentech’s Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening

    Updated Data Showed Genentech’s Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening

  7. UPDATE: Health savings accounts gain acceptance as retirement tool

    UPDATE: Health savings accounts gain acceptance as retirement tool

  8. Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic ...

    Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients

  9. Chip Firms Chase Deals to Address Margin, Pricing Pressures

    Chip Firms Chase Deals to Address Margin, Pricing Pressures

  10. IFS number one provider of EAM and FSM software for the oil and gas industry

    IFS number one provider of EAM and FSM software for the oil and gas industry

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.